Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7833210 | 0.91 | KMT2A (0.64) | AKR1C3AKR1C2KMT2AMEN1MAPT | |
| SCHEMBL1165640 | 0.89 | AKR1C3 (0.63) | AKR1C3AKR1C2KMT2AMEN1MAPT | |
| SCHEMBL28342284 | 0.85 | KMT2A (0.87) | KMT2AMEN1MAPTMAPK1HTT | |
| SCHEMBL31254103 | 0.85 | KMT2A (0.87) | KMT2AMEN1MAPTMAPK1HTT | |
| SCHEMBL515302 | 0.85 | LMNA (0.61) | AKR1C3AKR1C2KMT2AMEN1MAPT | |
| SCHEMBL28218708 | 0.85 | LMNA (0.61) | AKR1C3AKR1C2KMT2AMEN1MAPT | |
| SCHEMBL30059246 | 0.85 | LMNA (0.61) | AKR1C3AKR1C2KMT2AMEN1MAPT | |
| SCHEMBL394734 | 0.85 | KMT2A (0.67) | KMT2AMEN1MAPTHTTABCG2 | |
| SCHEMBL30612688 | 0.83 | NFE2L2 (0.59) | KMT2AMEN1MAPTMAPK1HTT | |
| SCHEMBL28090002 | 0.83 | NFE2L2 (0.59) | AKR1C3AKR1C2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11714080-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11692998-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210215671-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2021-07-15 | — | — | US | disclosed |
| US-20210215670-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2021-07-15 | — | — | US | disclosed |
| US-10955408-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200049693-A1 | COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORS | HMI Medical Innovations, LLC | 2020-02-13 | — | — | US | disclosed |
| US-10473643-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10018619-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170191986-A1 | Compounds and Method of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators | HMI Medical Innovations, LLC | 2017-07-06 | — | — | US | disclosed |
| US-9645137-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2017-05-09 | — | — | US | disclosed |
| US-9222933-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-8431110-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI MEDICAL INNOVATIONS, LLC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431110-B2 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI MEDICAL INNOVATIONS, LLC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20100016298-A1 | Theramutein modulators | HOUSEY GERAD M | 2010-01-21 | — | — | US | disclosed |
| US-20100016298-A1 | Theramutein modulators | HOUSEY GERAD M | 2010-01-21 | — | — | US | disclosed |
| US-20090275070-A1 | Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators | HOUSEY GERARD M | 2009-11-05 | — | — | US | disclosed |
| WO-2008091681-A2 | THERAMUTEIN MODULATORS | HOUSEY GERARD M (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
| US-20070111199-A1 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC | 2007-05-17 | — | — | US | disclosed |
| US-20070111199-A1 | Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016298-A1 | Theramutein modulators | TSG101, SERPINE1, PLAUR | AKR1C3 4292/4885AKR1C2 4096/4885KMT2A 3567/4885 |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K6 | AKR1C3 1098/4885AKR1C2 1204/4885KMT2A 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.